New 3-Drug Regimen for Leprosy in India

In January 2024, the Indian Ministry of Health and Family Welfare announced the approval of a new 3-drug regimen for the treatment of Pauci-Bacillary (PB) leprosy, set to start on April 1, 2025. This initiative replaces the existing 2-drug regimen and includes dapsone, rifampicin, and clofazimine. Endorsed by the World Health Organization (WHO), it is part of India’s commitment to eradicate leprosy by 2027, aligning with the United Nations’ Sustainable Development Goals. While this transition is expected to accelerate the eradication of leprosy and simplify treatment processes, there are concerns about its necessity and potential side effects, such as skin discoloration.